Ligand Pharmaceuticals Enters Worldwide Platform License Deal

Ligand Pharmaceuticals has entered into a worldwide license agreement with Menlo Park, Calif.-based xCella Biosciences Inc., the company said Tuesday.

Under the license, xCella will be able to use Ligand’s OmniRat, OmniMouse and OmniFlic platforms to discover fully human mono- and bispecific antibodies. Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments and royalties for each product incorporating an OmniAb antibody. xCella will be responsible for all costs related to the programs.

By Stephen Holmes